Category - Developments

Developments

Genflow and CER agree to long-term R&D collaboration

Genflow Biosciences (LSE:GENF; OTCQB:GENFF) has announced the signing of a master service agreement (MSA) with closely held CER Groupe—a long-standing partner—to strengthen long-term research and development (R&D)...

May 28, 2025

Developments

NeoGenomics introduces PanTracer genomic profiling tests at ASCO 2025

NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025...

May 28, 2025

Developments

Perimeter partners with Intermountain Health to study benefits of using OCT and AI to reduce cancer reoperations

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has entered into a development support agreement with Intermountain Health, creating the framework for the two organizations to partner on a...

May 23, 2025

Developments

FDA clears Quoin’s second QRX003 NS pivotal study

Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has provided clearance to initiate a second Netherton Syndrome (NS) clinical pivotal study—CL-QRX003-002, for Quoin’s lead product QRX003. According to Quoin...

May 22, 2025

Developments

NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic

NorthStrive Biosciences (NASDAQ:ELAB) announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic targeting...

May 22, 2025

Developments

Zura Bio launches global Phase 2 study of tibulizumab in HS

Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe...

May 21, 2025

Developments

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

Neurogene (NASDAQ:NGNE) has announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting this week describing a monitoring and treatment algorithm intended to reverse the rare...

May 16, 2025

Developments

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting

CAMP4 Therapeutics (NASDAQ:CAMP) has announced that three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs, and shared favorable safety and pharmacokinetics data from the...

May 16, 2025

Developments

Ekso Bionics accepted into NVIDIA Connect program

Ekso Bionics Holdings (NASDAQ:EKSO) has announced its acceptance into the NVIDIA Connect program, enabling access to valuable tools and resources to support a new strategic initiative to build a proprietary foundation...

May 15, 2025

Developments

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

In a May 13, 2025 post on X, Chamath Palihapitiya, renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, provided the latest updates on Perimeter Medical Imaging AI (TSXV:PINK;...

May 14, 2025

Category - Developments

Subscribe